Gene · 4175
Papers2,153
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
301 to 320 of 2,153
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Metabolomic, Lipidomic, Transcriptomic, and Metagenomic Analyses in Mice Exposed to PFOS and Fed Soluble and Insoluble Dietary Fibers. | Environ Health Perspect | 2022 | 36331819 | PubTator, text mining | PubMed |
| Identification of Master Regulators Driving Disease Progression, Relapse, and Drug Resistance in Lung Adenocarcinoma. | Front Bioinform | 2022 | 36304306 | PubTator, text mining | PubMed |
| MCM2 in human cancer: functions, mechanisms, and clinical significance. | Mol Med | 2022 | 36303105 | PubTator, text mining | PubMed |
Identification of EGFR-Related LINC00460/mir-338-3p/MCM4 Regulatory Axis as Diagnostic and Prognostic Biomarker of Lung Adenocarcinoma Based on Comprehensive Bioinformatics Analysis and Experimental Validation. | Cancers (Basel) | 2022 | 36291859 | PubTator, text mining | PubMed |
| UBE2O promotes lipid metabolic reprogramming and liver cancer progression by mediating HADHA ubiquitination. | Oncogene | 2022 | 36273042 | PubTator, text mining | PubMed |
| Cellular basis of enhanced humoral immunity to SARS-CoV-2 upon homologous or heterologous booster vaccination analyzed by single-cell immune profiling. | Cell Discov | 2022 | 36270988 | PubTator, text mining | PubMed |
| Construction and validation of a prognostic marker and risk model for HCC ultrasound therapy combined with WGCNA identification. | Front Genet | 2022 | 36263426 | PubTator, text mining | PubMed |
| TIF1γ inhibits lung adenocarcinoma EMT and metastasis by interacting with the TAF15/TBP complex. | Cell Rep | 2022 | 36261009 | PubTator, text mining | PubMed |
| GPI: An indicator for immune infiltrates and prognosis of human breast cancer from a comprehensive analysis. | Front Endocrinol (Lausanne) | 2022 | 36246907 | PubTator, text mining | PubMed |
| High-Level MYCN-Amplified RB1-Proficient Retinoblastoma Tumors Retain Distinct Molecular Signatures. | Ophthalmol Sci | 2022 | 36245757 | PubTator, text mining | PubMed |
| Solving the MCM paradox by visualizing the scaffold of CMG helicase at active replisomes. | Nat Commun | 2022 | 36241664 | PubTator, text mining | PubMed |
| Novel Insights into Redox-Based Mechanisms for Auranofin-Induced Rapid Cancer Cell Death. | Cancers (Basel) | 2022 | 36230784 | PubTator, text mining | PubMed |
| Construction of novel lncRNA-miRNA-mRNA ceRNA networks associated with prognosis of hepatitis C virus related hepatocellular carcinoma. | Heliyon | 2022 | 36217480 | PubTator, text mining | PubMed |
| Distinct roles of ORAI1 in T cell-mediated allergic airway inflammation and immunity to influenza A virus infection. | Sci Adv | 2022 | 36206339 | PubTator, text mining | PubMed |
| Identifying the genes impacted by cell proliferation in proteomics and transcriptomics studies. | PLoS Comput Biol | 2022 | 36201535 | PubTator, text mining | PubMed |
| HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans. | Clin Cancer Res | 2022 | 36190432 | PubTator, text mining | PubMed |
| MCM6 is a critical transcriptional target of YAP to promote gastric tumorigenesis and serves as a therapeutic target. | Theranostics | 2022 | 36185598 | PubTator, text mining | PubMed |
| ARHGAP24 represses β-catenin transactivation-induced invasiveness in hepatocellular carcinoma mainly by acting as a GTPase-independent scaffold. | Theranostics | 2022 | 36168627 | PubTator, text mining | PubMed |
| HOXA5 inhibits the proliferation of extrahepatic cholangiocarcinoma cells by enhancing MXD1 expression and activating the p53 pathway. | Cell Death Dis | 2022 | 36167790 | PubTator, text mining | PubMed |
| Identification of the genetic central dogma in osteogenic differentiation of MSCs by osteoinductive medium from transcriptional data sets. | Chronic Dis Transl Med | 2022 | 36161200 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4175/papers?page=16